Differences in Clinical Characteristics and one-year outcomes of Hospitalized Heart Failure Patients in succeeding ESC-HF Registries ? Pilot and Long-Term

Balsam, Paweł; Ozierański, Krzysztof; Kapłon‐Cieślicka, Agnieszka; Borodzicz, Sonia; Tymińska, Agata; Peller, Michał; Marchel, Michał; Leiro, María G. Crespo; Maggioni, Aldo P.; Dróżdż, Jarosław; Kołtowski, Łukasz; Filipiak‬, Krzysztof J.; Straburzyńska‐Migaj, Ewa; Opolski, Grzegorz; Grabowski, Marcin

doi:10.4172/2165-7548.1000382

Cited by 8 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the fact that only patients who purchased at least one of the classic drugs increasing survival were eligible for the study, in our cohort a lesser percentage of patients lled prescriptions for CV drugs comparing treatment at discharge in mentioned above Polish cohorts of European registries. While the difference regarding ACEi and ARB was approximately 10%, and for MRA approx 20 %, in case of BB, diuretics, digoxine, statins the percentage was twice smaller [17].…”

Section: Discussionmentioning

confidence: 84%

“…Similarly to other registers that included acute HF patients, there was a high long-term mortality despite the fact that we excluded patients who died or were readmitted early [18,19]. Also one-year mortality was 50% higher than reported in Polish cohorts of European registries [17].…”

Section: Discussionmentioning

confidence: 86%

“…Compared to classic registry data, the patients in our study were 5 to 9 years older [10][11][12][13][14][15][16][17].…”

Section: Discussionmentioning

confidence: 99%

“…Balsam et al analysed n = 1415 hospitalized patients from Polish cohorts of both ESC-HF Pilot and ESC-HF-LT registries [17]. The mean age was lower (69 yrs.)…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Impact of Alpha-Adrenergic Receptor Antagonists on outcomes in patients with heart failure. A post-hoc analysis using National Health Fund database

Symonides

Lewandowski

Śliwczyński

2021

Preprint

View full text Add to dashboard Cite

BackgroundThe alpha-adrenolytics (AA) are not recommended in patients with EF reduced heart failure due to safety concerns. The aim of our study was to assess the safety of AA in patients hospitalized due to exacerbation of HF and the influence of these drugs on long-term endpoints.MethodsData collected by the National Health Fund was used. Patients hospitalized due to HF exacerbation were included. The primary outcome was all-cause mortality and the secondary was the first readmission due to HF or all-cause death occurring more than 30 days after discharge.ResultsOf 140 668 patients hospitalized in the year 2013 n=53317 were included and followed for a median of 56.3 months. AA patients had lower long-term mortality (52.8% vs. 54.9%, unadjusted P=0.038). The treatment with AA positively and affected long-term survival (adjHR 0.82, 95%CI 0.78-0.87, P<0.001), as well as secondary endpoint (adjHR 0.85, 95%CI 0.81-0.90, P<0.001).Cox analysis in the subgroup treated with beta-blockers revealed that treatment with AA was associated with lower mortality (adjHR 0.82, 95%CI 0.75-0.90, P<0.001) and lower incidence of secondary endpoint (adjHR 0.85, 95%CI 0.78-0.92, P<0.001). ConclusionsIn compliant patients hospitalized due to HF exacerbation post discharge treatment with AA was safe and beneficial.

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 86%

See 2 more Smart Citations

Impact of Alpha-Adrenergic Receptor Antagonists on outcomes in patients with heart failure. A post-hoc analysis using National Health Fund database

Symonides

Lewandowski

Śliwczyński

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Its incidence increases with age. It is reported to be the most common cardiovascular reason for hospitalization in people over 60 years of age and carries a poor prognosis [1][2][3] . It not only greatly impairs an individual's life quality and expectancy but also imposes a heavy burden on the health care system.…”

Section: Introductionmentioning

confidence: 99%

Assessment of the risk of incident heart failure in osteoporosis patients: a systematic review and meta-analysis of eligible cohort studies

Gu¹,

Yang²,

Zhang³

et al. 2020

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only.

show abstract

miRNAs in the development of left ventricular remodeling and post-myocardial infarction heart failure

Sygitowicz

Maciejak-Jastrzębska

Sitkiewicz

2020

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Acute myocardial infarction (AMI) induces unfavorable left ventricular remodeling (LVR), a complex process that involves molecular, cellular, and geometric alterations leading to important changes in heart structure and function. Heart failure (HF) is a frequent complication of AMI, and it remains a serious clinical, epidemiological, and economic challenge. Despite advances in the therapy and management of HF, many patients still suffer from severe symptoms. The underlying molecular mechanisms of the post -AMI LVR are not yet fully understood. Numerous studies have indicated that dysregulation in the expression of microRNA (miRNA) molecules leads to changes in several pathological processes in the heart, which are associated with post -AMI transition from cardiac hypertrophy to HF. In this review, we summarize the current knowledge on the role of miRNAs in the regulation of basic processes, such as excessive myocardial fibrosis, pathological cardiomyocyte hypertrophy, and myocardial cell apoptosis. Moreover, the significance of circulating miRNAs as noninvasive prognostic biomarkers in the prediction of LVR and HF after AMI has also been discussed. In conclusion, miR -29 family members (miR -29a and miR--29b), miR -150, and miR -30a -5p represent different groups of miRNAs, but all of them are involved in the regulation of the fundamental processes associated with post -AMI left ventricular dysfunction and HF. Furthermore, these miRNA molecules may serve as a potential therapeutic target during disease progression.

show abstract

Differences in Clinical Characteristics and one-year outcomes of Hospitalized Heart Failure Patients in succeeding ESC-HF Registries ? Pilot and Long-Term

Cited by 8 publications

References 0 publications

Impact of Alpha-Adrenergic Receptor Antagonists on outcomes in patients with heart failure. A post-hoc analysis using National Health Fund database

Impact of Alpha-Adrenergic Receptor Antagonists on outcomes in patients with heart failure. A post-hoc analysis using National Health Fund database

Assessment of the risk of incident heart failure in osteoporosis patients: a systematic review and meta-analysis of eligible cohort studies

miRNAs in the development of left ventricular remodeling and post-myocardial infarction heart failure

Contact Info

Product

Resources

About